Read by QxMD icon Read


Chong Hyun Suh, Ho Sung Kim, Seung Chai Jung, Choong Gon Choi, Sang Joon Kim
Background: Noninvasive and accurate modality to predict Isocitrate dehydrogenase (IDH) mutant glioma may have great potential in routine clinical practice. We aimed to investigate the diagnostic performance of 2-hydroxyglutarate (2HG) magnetic resonance spectroscopy (MRS) for prediction of IDH mutant glioma and provide an optimal cut-off value for 2HG. Methods: A systematic literature search of Ovid-MEDLINE and EMBASE was performed to identify original articles investigating the diagnostic performance of 2HG MRS up to March 20, 2018...
July 18, 2018: Neuro-oncology
Johannes Nowak, Karolina Nemes, Annika Hohm, Lindsey A Vandergrift, Martin Hasselblatt, Pascal D Johann, Marcel Kool, Michael C Frühwald, Monika Warmuth-Metz
Background: Recently, three molecular subgroups of atypical teratoid/rhabdoid tumor (ATRT) were identified, but little is known on their clinical and magnetic resonance imaging (MRI) characteristics. Methods: A total of 43 patients with known molecular subgroup status (ATRT-SHH n=17, ATRT-TYR n=16, ATRT-MYC n=10) were retrieved from the EU-RHAB registry and analyzed for clinical and MRI features. Results: On MRI review, differences in preferential tumor location were confirmed, with ATRT-TYR being predominantly located infratentorially (p<...
July 13, 2018: Neuro-oncology
Sabine Spiegl-Kreinecker, Daniela Lötsch, Katharina Neumayer, Lucia Kastler, Johannes Gojo, Christine Pirker, Josef Pichler, Serge Weis, Rajiv Kumar, Gerald Webersinke, Andreas Gruber, Walter Berger
Background: Meningiomas are mostly benign tumors tending to progress to higher-grade lesions. Mutations in the telomerase reverse transcriptase (TERT) gene promoter are comparably rare in meningioma, but were recently suggested to predict risk of recurrence and progression. Here we have analyzed a cohort of World Health Organization grades I-III meningiomas regarding the impact of TERT promoter mutations on patient prognosis and in vitro cell propagation feasibility. Methods: From 110 meningioma patients, 128 tissue samples were analyzed for the TERT promoter mutations C228T and C250T by direct sequencing...
July 11, 2018: Neuro-oncology
(no author information available yet)
No abstract text is available yet for this article.
July 10, 2018: Neuro-oncology
Andrew B Lassman, Martin J van den Bent, Hui K Gan, David A Reardon, Priya Kumthekar, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B Nabors, Kyriakos P Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Tobias Walbert, Andrew M Scott, Erica Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Peter J Ansell, Earle Bain, Kyle D Holen, David Maag, Ryan Merrell
Background: Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells with EGFR amplification, is internalized, and releases a microtubule toxin, killing the cell. Here we report efficacy, safety and pharmacokinetics (PK) of depatux-m + temozolomide (TMZ) in patients with EGFR-amplified rGBM...
July 5, 2018: Neuro-oncology
Patrick J Cimino, Lisa McFerrin, Hans-Georg Wirsching, Sonali Arora, Hamid Bolouri, Raul Rabadan, Michael Weller, Eric C Holland
Background: Copy number alterations form prognostic molecular subtypes of glioblastoma with clear differences in median overall survival. In this study, we leverage molecular data from several glioblastoma cohorts to define the distribution of copy number subtypes across random cohorts as well as cohorts with selection biases for patients with inherently better outcome. Methods: Copy number subtype frequency was established for four glioblastoma patient cohorts...
July 2, 2018: Neuro-oncology
Eudocia Quant Lee, J Ricardo McFaline-Figueroa, Timothy F Cloughesy, Patrick Y Wen
No abstract text is available yet for this article.
June 27, 2018: Neuro-oncology
Signe R Michaelsen, Mikkel Staberg, Henriette Pedersen, Kamilla E Jensen, Wiktor Majewski, Helle Broholm, Mette K Nedergaard, Christopher Meulengracht, Thomas Urup, Mette Villingshøj, Slávka Lukacova, Jane Skjøth-Rasmussen, Jannick Brennum, Andreas Kjær, Ulrik Lassen, Marie-Thérése Stockhausen, Hans S Poulsen, Petra Hamerlik
Background: Glioblastoma ranks among the most lethal cancers with current therapies offering only palliation. Paracrine vascular endothelial growth factor (VEGF) signaling has been targeted using anti-angiogenic agents, whereas autocrine VEGF/VEGF Receptor 2 (VEGFR2) signaling is poorly understood. Bevacizumab resistance of VEGFR2-expressing glioblastoma cells prompted interrogation of autocrine VEGF-C-VEGFR2 signaling in glioblastoma. Methods: Autocrine VEGF-C/VEGFR2 signaling was functionally investigated using RNA interference and exogenous ligands in patient-derived xenograft lines and primary glioblastoma cell cultures in vitro and in vivo...
June 25, 2018: Neuro-oncology
Jason K Sa, Sung Heon Kim, Jin-Ku Lee, Hee Jin Cho, Yong Jae Shin, Hyemi Shin, Harim Koo, Donggeon Kim, Mijeong Lee, Wonyoung Kang, Sung Hee Hong, Jung Yong Kim, Young-Whan Park, Seong-Won Song, Song-Jae Lee, Kyeung Min Joo, Do-Hyun Nam
Background: Cancer is a complex disease with profound genomic alterations and extensive heterogeneity. Recent studies on a large-scale genomics have shed lights on the impact of core oncogenic pathways which are frequently dysregulated in a wide spectrum of cancer types. Aberrant activation of hepatocyte growth factor (HGF) signaling axis has been associated with promoting various oncogenic programs during tumor initiation, progression, and treatment resistance. As a result, HGF-targeted therapy has emerged as an attractive therapeutic approach...
June 23, 2018: Neuro-oncology
Sangeet Lal, Diego Carrera, Joanna J Phillips, William A Weiss, Corey Raffel
Background: Oncolytic measles virus (MV) is effective in xenograft models of many tumor types in immune-compromised mice. However, no murine cell line exists that is tumorigenic, grows in immune-competent mice, and is killed by MV. The lack of such a model prevents an examination of the effect of the immune system on MV oncotherapy. Methods: Cerebellar stem cells from human CD46-transgenic immunocompetent mice were transduced to express Sendai virus C-protein, murine C-Myc, and Gfi1b proteins...
June 14, 2018: Neuro-oncology
Christina Amidei
Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them produce symptoms that affect an individual's ability to function in everyday life. Common symptoms include fatigue, cognitive impairment, distress, and sleep disturbance. Symptom-based interventions for persons with brain tumors focus on prevention, self-management and prescriptive interventions targeted to these problems...
June 13, 2018: Neuro-oncology
Desmond A Brown, Benjamin T Himes, Panagiotis Kerezoudis, Yirengah M Chilinda-Salter, Sanjeet S Grewal, Joshua A Spear, Mohamad Bydon, Terry C Burns, Ian F Parney
Background: The current standard of care for glioblastoma (GBM) constitutes maximal safe surgical resection, followed by fractionated radiation and temozolomide. This treatment regimen is logistically burdensome, and in a healthcare system in which access to care is variable, there may be patients with worsened outcomes due to inadequate access to optimal treatment. Methods: The National Cancer Database was queried for patients diagnosed with GBM in 2006-2014. Patients were grouped according to insurance status: private insurance, Medicare, Medicaid, or uninsured...
June 11, 2018: Neuro-oncology
Mathias Kunz, Nathalie Lisa Albert, Marcus Unterrainer, Christian la Fougere, Rupert Egensperger, Ulrich Schüller, Juergen Lutz, Simone Kreth, Jörg-Christian Tonn, Friedrich-Wilhelm Kreth, Niklas Thon
Background: We aimed to elucidate the place of dynamic 18F-FET-PET in prognostic models of gadolinium (Gd)-negative gliomas. Methods: In 98 patients with Gd-negative gliomas undergoing 18F-FET-PET guided biopsy, time activity curves (TAC) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTPmin) measurements. Prognostic factors were obtained from multivariate hazards models...
June 9, 2018: Neuro-oncology
Alberto Falk Delgado, Francesca De Luca, Danielle van Westen, Anna Falk Delgado
Background: Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of Arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods: Cochrane Library, Embase, Medline and Web of Science Core Collection were searched. Study selection until November 2017. This study was prospectively registered in Prospero (CRD42017080885)...
June 2, 2018: Neuro-oncology
Line Kenborg, Jeanette Falck Winther, Karen Markussen Linnet, Anja Krøyer, Vanna Albieri, Anna Sällfors Holmqvist, Laufey Tryggvadottir, Laura Maria Madanat-Harjuoja, Marilyn Stovall, Henrik Hasle, Jørgen H Olsen
Backgorund: A comprehensive overview of neurologic complications among survivors of central nervous system (CNS) tumors in childhood is lacking. We aimed to investigate the risk for these disorders in a large, population-based study with outcome measures from nationwide hospital registries. Methods: We identified 4,858 five-year survivors diagnosed with a CNS tumor in childhood in Denmark, Iceland, Finland, and Sweden in 1943-2007, and 166,658 matched population comparison subjects...
May 30, 2018: Neuro-oncology
Daniel W Fults
No abstract text is available yet for this article.
May 30, 2018: Neuro-oncology
Haley Gittleman, Alexander Boscia, Quinn T Ostrom, Gabrielle Truitt, Yi Fritz, Carol Kruchko, Jill S Barnholtz-Sloan
Background: The goal of this study was to provide up to date and comprehensive statistics on incidence, survival, and prevalence rates for selected malignant brain and other CNS tumors in adults. Methods: The current study used CBTRUS data, provided by CDC, to examine incidence and SEER data to examine survival and prevalence in sixteen distinct malignant brain and other CNS histologies in adults (aged 20 years and older at diagnosis) from 2000-2014 overall and by sex, age group, race, and ethnicity...
May 29, 2018: Neuro-oncology
Lei Zhang, Liqun He, Roberta Lugano, Kenney Roodakker, Michael Bergquist, Anja Smits, Anna Dimberg
Background: Vascular gene expression patterns in lower grade gliomas (LGG, diffuse WHO grade II-III gliomas) have not been thoroughly investigated. The aim of this study was to molecularly characterize LGG vessels and determine if tumor isocitrate dehydrogenase (IDH)-mutation status affects vascular phenotype. Methods: Gene expression was analyzed using an in-house dataset derived from microdissected vessels and total tumor samples from human glioma in combination with expression data from 289 LGG samples available in the TCGA database...
May 29, 2018: Neuro-oncology
Archya Dasgupta, Tejpal Gupta, Sona Pungavkar, Neelam Shirsat, Sridhar Epari, Girish Chinnaswamy, Abhishek Mahajan, Amit Janu, Aliasgar Moiyadi, Sadhana Kannan, Rahul Krishnatry, Jayant Sastri Goda, Rakesh Jalali
Background: Novel biological insights have led to consensus classification of medulloblastoma into four distinct molecular subgroups - wingless (WNT), sonic hedgehog (SHH), Group 3, and Group 4. We aimed to predict molecular subgrouping in medulloblastoma based on pre-operative multi-parametric magnetic resonance imaging (MRI) characteristics. Methods: A set of 19 MRI features were evaluated in 111 patients with histologic diagnosis of medulloblastoma for prediction of molecular subgrouping...
May 29, 2018: Neuro-oncology
Nicholas F Brown, Matthew Williams, Hendrik-Tobias Arkenau, Ronald A Fleming, Jerry Tolson, Li Yan, Jianping Zhang, Lisa Swartz, Rajendra Singh, Kurt R Auger, Laurie Lenox, David Cox, Yvonne Lewis, Christophe Plisson, Graham Searle, Azeem Saleem, Sarah Blagden, Paul Mulholland
Background: GSK2256098 is a novel oral focal adhesion kinase inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood-brain barrier penetration. In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics and clinical activity of GSK2256098 were evaluated in patients with recurrent glioblastoma. Biodistribution and kinetics of [11C]GSK2256098 were assessed in a sub-study using positron-emission tomography (PET)...
May 17, 2018: Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"